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ABSTRACT: Whey protein intake is associated with the modulation
of energy metabolism and altered body composition both in human
subjects and in animals, but the underlying mechanisms are not yet
elucidated. We fed obesity-prone C57BL/6J mice high-fat diets with
either casein (HF casein) or whey (HF whey) for 6 weeks. At equal
energy intake and apparent fat and nitrogen digestibility, mice fed HF
whey stored less energy as lipids, evident both as lower white adipose
tissue mass and as reduced liver lipids, compared with HF-casein-fed
mice. Explorative analyses of 48 h urine, both by 1H NMR and LC−
MS metabolomic platforms, demonstrated higher urinary excretion of
tricarboxylic acid (TCA) cycle intermediates citric acid and succinic
acid (identiﬁed by both platforms), and cis-aconitic acid and isocitric
acid (identiﬁed by LC−MS platform) in the HF whey, relative to in the HF-casein-fed mice. Targeted LC−MS analyses revealed
higher citric acid and cis-aconitic acid concentrations in fed state plasma, but not in liver of HF-whey-fed mice. We propose that
enhanced urinary loss of TCA cycle metabolites drain available substrates for anabolic processes, such as lipogenesis, thereby
leading to reduced lipid accretion in HF-whey-fed compared to HF-casein-fed mice.
KEYWORDS: obesity, adipose tissue, metabolomics, whey, casein, tricarboxylic acid cycle, citric acid cycle, Krebs cycle, lipogenesis,
glutaminolysis
■ INTRODUCTION
Obesity has reached pandemic proportions, and between 1980
and 2008 the mean body mass index (BMI) worldwide was
estimated to have increased by 0.4 and 0.5 kg/m2 per decade
for men and women, respectively.1 Understanding how
environmental factors, such as diet, aﬀect the development of
obesity is important. From cross-sectional studies, an inverse
relationship between dairy consumption and BMI has been
suggested.2,3 More speciﬁcally, inclusion of dairy products
during energy-restricted weight loss resulted in higher fat mass
reduction while maintaining lean body mass.4−6 In further
support of a fat-reducing eﬀect of milk-proteins, a randomized
controlled study with overweight subjects showed that intake of
milk protein for 20 weeks reduced both visceral and
subcutaneous fat more than intake of soy protein.7
Milk protein consists of about 80% casein and 20% whey, but
casein and whey proteins are likely to aﬀect metabolism
diﬀerently. A randomized, double-blinded intervention study
with crossover design demonstrated that after ingestion of a
liquid test meal consisting of 50% protein, 40% carbohydrate,
and 10% fat, whey protein induced a higher postprandial
thermic eﬀect than both casein and soy protein.8 In another
intervention study with free-living overweight and obese
subjects, intake of whey protein but not soy protein (both
∼56g protein/day for 23 weeks) resulted in a signiﬁcant
reduction in body mass, fat mass, and waist circumference,
relative to the carbohydrate (maltodextrin) control treatment.9
Thus, data from human studies indicate that whey protein
induces diﬀerent eﬀects on energy metabolism than do both
casein and soy protein.
This notion is further supported by studies using the obesity
prone C57BL/6J mice fed high-fat diets with either whey or
casein as protein sources. In a study including a period of 50
days with energy restriction before 50 days with free access to
feed (weight regain period), whey protein dose-dependently
prevented weight regain and protected against fatty liver
development relative to casein during the weight regain
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period.10 Importantly, neither energy intake nor apparent fat
digestibility was reduced by whey protein feeding.10 Two other
studies have conﬁrmed the ability of whey protein, relative to
casein, to reduce adiposity in high-fat-fed C57BL/6J mice at
equal energy intake.11,12
On the basis of existing data from human and mice studies,
dietary whey protein has been shown to elicit a weight-reducing
eﬀect, with speciﬁc reduction in fat mass. The underlying
mechanisms governing reduced adiposity by whey ingestion are
yet to be established. Therefore, the aim of the present study
was to further elaborate our understanding of the antiobesity
eﬀects of whey protein intake. For this purpose, we fed obesity-
prone C57BL/6J mice high-fat diets (20 energy % protein, 60
energy % fat) with either casein or whey protein as the sole
protein source. Samples from the mice were analyzed by
biochemical and molecular methods, explorative NMR-based
and LC−MS-based metabolomics, as well as targeted LC−MS
metabolomics. In whey-fed mice, our results identify a potential
mechanism by loss of energy through enhanced urinary
excretion of tricarboxylic acid (TCA) intermediates. Our
metabolomic analyses provided novel knowledge on how
diﬀerent protein sources may aﬀect energy metabolism,
indicating that at equal energy intake and with equal fat and
nitrogen digestibility, HF whey feeding prevented body fat gain
by increasing urinary excretion of TCA intermediates, thereby
reducing the availability of these for anabolic processes in the
body as compared with HF casein feeding.
■ EXPERIMENTAL PROCEDURES
Ethical Statement
The animal experiments were approved by the National Animal
Health Authorities. Care and handling were in accordance with
local institutional recommendations and rules. Adverse events
were not observed.
Animal Studies and Diets
Male C57BL/6JBomTac aged 8 to 9 weeks were purchased
from Taconic, Denmark. After 5 days of acclimatization, the
mice were assigned to one of three dietary treatments: (I) HF
casein (n = 14), a casein-based very high-fat diet (60en% fat
and 20en% protein, D12492, Research Diets, USA), (II) HF
whey (n = 14), a whey-protein-based very high-fat diet (60 en%
fat and 20 en% protein), or (III) LF reference (n = 12), a
casein-based low-fat diet, (D12450B, Research Diets, USA)
(Table S1 Supporting Information). The mice were housed in
individual cages and had free access to food and water. The
mice were maintained on a 12:12 h light-dark cycle at
thermoneutrality, 28 ± 1 °C. The mice were fed Mondays,
Wednesdays, and Fridays, and body mass was recorded once a
week. Leftover feed was quantitatively collected from the cages
every other week. During the fourth week of the feeding period,
a subpopulation of the mice (LF reference, n = 6; HF casein
and HF whey, n = 8/treatment) spent 48 h in wire-bottomed
cages for urine collection for metabolomic studies. Urine was
collected in 0.5 mL of 1 mol/L HCl and frozen after 24 and 48
h. After feeding for 42−46 days in the nonfasted state (free
access to food until termination), the mice were anesthetized
with isoﬂurane (Isoba vet, Schering-Plough, Denmark) and
euthanized by cardiac puncture. Blood was collected, and
heparin plasma was prepared and frozen at −80 °C. Tissues
were quickly dissected out and weighted. From a subpopulation
of mice (LF, n = 6; HF casein and HF whey, n = 8), a part of
the liver was homogenized for ex vivo hepatic fatty acid
oxidation capacity measurements. Samples were taken from the
epididymal and inguinal white adipose tissues (eWAT and
iWAT, respectively) and ﬁxed for histology. The rest of the
tissues were quickly snap-frozen in liquid nitrogen and stored at
−80 °C. From all mice (n = 12 or 14/group), liver, skeletal
muscle tibialis anterior, eWAT, iWAT, and interscapular brown
adipose tissue (iBAT) were dissected out. Additionally, from a
subpopulation of the mice (n = 6−8/group), kidneys, heart,
and skeletal muscle soleus were dissected out. An overview of
the study design is presented in Figure S1 (Supporting
Information). A separate set of mice (n = 10/diet) was fed
the HF casein or the HF whey diet to determine apparent fat
and nitrogen digestibility. Food intake and feces excretion was
quantiﬁed during the last 5 days.
Gross Energy in the Experimental Diets
The gross energy contents were determined in a bomb
calorimeter following the manufacturer’s instruction (Parr
Instruments, Moline, IL).
Amino Acid Composition in the HF Diets
Amino acids in the diets were analyzed by standard
methodology, as described in detail in the Supporting
Information.
Total Fat in Diets and Feces
Total fat content was determined gravimetrically after
extracting samples with organic solutions before and after
acidic hydrolysis of the samples, as described in detail
elsewhere.13
Nitrogen in Diets and Feces
The nitrogen (N) content was determined by the Dumas
method in a Leco FP-528 nitrogen analyzer (LECO Corp., St.
Joseph, MI). The crude protein content in the diets was
calculated as N × 6.25.
Apparent Fat and Nitrogen Digestibility
Feces were weighted and analyzed for nitrogen and total fat
content. Fat and nitrogen apparent digestibility were calculated
as 100((eaten (mg) − fecal output (mg))/(eaten (mg)).
Histology
Sections of adipose tissue were ﬁxed in 4% formaldehyde in 0.1
mol/L phosphate buﬀer overnight at 4 °C, washed in 0.1 mol/L
PB, dehydrated in ethanol, and embedded in paraﬃn after
clearing with xylene. Then, 5 μm thick sections of the
embedded tissue were stained with eosin and hematoxylin.
Quantitative Reverse-Transcriptase PCR
From a subpopulation of the mice (n = 6−8/diet), RNA was
puriﬁed, cDNA was synthesized, and quantitative reverse-
transcriptase PCR (qRT-PCR) was run as previously described
in detail.14 GeNorm was used to determine the most suitable
normalization gene for each tissue; therefore, Tbp (TATA box
binding protein) was used for normalization of gene expression
in iWAT and iBAT, Actb (β-actin) was used for normalization
in soleus skeletal muscle, and Canx (calnexin) was used in liver.
Primers for qRT-PCR were designed using Primer Express 2.0
(Applied Biosystems, USA) and are presented in Table S2 in
the Supporting Information.
Plasma Measurements
Plasma measurements were made on a subpopulation of the
mice (n = 6−8/diet). Leptin and insulin concentrations were
analyzed by ELISA kits (Leptin: BioVendor, Czech Republic;
Insulin: DRG Diagnostics, Germany). Glucagon and adipo-
Journal of Proteome Research Article
dx.doi.org/10.1021/pr500039t | J. Proteome Res. 2014, 13, 2560−25702561
nectin we measured by radioimmunoassay kits (Glucagon:
Millipore, USA; Adiponectin: LINCO Research, USA). Plasma
β-hydroxybutyrate (OH-butyrate), triacylglycerol (TAG), free
fatty acids (FFA), glucose, and lactate concentrations were
analyzed by conventional enzymatic kits (β-hydroxybutyrate:
Randox, United Kingdom; TG, FFA, and glucose: DIALAB,
Austria; lactate: Sentinel Diagnostics, Italy) using a MaxMat PL
II (MAXMAT S.A., Montpellier, France).
Liver Lipid Analysis
From a subpopulation of the mice (n = 6/diet), total lipids
were extracted from liver samples with chloroform/methanol
2:1 (v:v). The lipid classes were analyzed on an automated
Camaq HPTLC system and separated on HPTLC silica gel 60
F plates, as previously described.15
Liver β-Oxidation Capacity Measurement
From a subpopulation of the mice (LF n = 6; HF casein and
HF whey, n = 8), one part of liver tissue was immediately after
sampling homogenized in nine parts (w/v) ice-cold homoge-
nization buﬀer (200 mM mannitol, 50 mM sucrose, 10 mM
HEPES-KOH, 1 mM EDTA, 0.1% fatty acid free BSA, pH
7.4).16 Fatty acid oxidation capacity was measured in the whole
homogenate by the acid-soluble product method using
radiolabeled palmitate as the substrate, as previously described
in detail17 and in the Supporting Information.
Metabolomic Analyses by 1H Nuclear Magnetic Resonance
(NMR) Spectroscopy
From a subpopulation of mice (LF ref, n = 6; HF diets, n = 8/
diet), urine samples were analyzed by NMR spectroscopy. The
NMR measurements were performed using a Bruker Avance
600 NMR spectrometer (Bruker BioSpin, Rheinstetten,
Germany), operating at a 1H frequency of 600.13 MHz and
equipped with a 5 mm TXI inverse probe. Urine samples were
prepared by mixing 200 μL of urine with 400 μL of D2O
containing 0.05% sodium trimethylsilyl-[2,2,3,3-2H4]-1-propio-
nate (TSP). Prior to NMR measurements, the urine samples
were adjusted to pH 5.5, as this value was close to the actual pH
of the urine. Standard 1D 1H NMR spectra were obtained using
single 90° degree pulse experiment with water suppression
achieved by irradiating the water peak during the relaxation
delay. The spectra were acquired by 64 scans, 32k data points, a
spectral width of 17.34 ppm, and a temperature of 310 K. An
exponential line-broadening of 0.3 Hz was applied prior to the
Fourier transformation. Each spectrum was manually phased,
baseline-corrected, and referenced to TSP. Two-dimensional
(2D) NMR experiments were performed on selected samples
to assist tentative assignment by online databases such as the
Human Metabolome Database (HMDB).18 The 2D-NMR
experiments conﬁrmed that the diﬀerence in pH between urine
samples in the present study (5.5) and the pH of the
compounds in the HMDB set to 7.0 did not inﬂuence on
compound assignments. Prior to the multivariate data analysis,
spectra were aligned using the icoshift procedure19 in MATLAB
(version R2009b, The Mathworks, Natick, MA). The water
signal was excluded by removing the region from 4.7 to 4.9
ppm. Subsequently, the spectra were subdivided into 0.007
ppm spectral regions and integrated. The data sets were
normalized to total area to remove any overall eﬀects of
diﬀerential dilution of the samples. Supervised orthogonal
partial least-squares discriminant analysis (O-PLS-DA) was
performed using the SIMCA-P+ software version 13.0
(Umetrics AB, Umea,̊ Sweden) on the mean-centered and
Pareto-scaled data and with full cross-validation (leave-one-
out). The quality of the models was evaluated by R2X,
describing how much of the variation that is explained by the
model (goodness of ﬁt), and Q2, representing the predictive
ability of the model (goodness of prediction) and the cross-
validation ANOVA feature in SIMCA-P+.
Sample Preparation for Liquid Chromatography−Mass
Spectrometry (LC−MS)
From a subpopulation of mice (n = 6−8) LC−MS
metabolomic analyses were performed in urine, liver and
plasma samples. Urine was diluted 5 times with 0.1% formic
acid prior to LC−MS analysis. Heparin plasma samples were
mixed with methanol to a ﬁnal concentration of 80% methanol
and precipitation proceeded for 30 min at room temperature.
After centrifugation (20 000g, 20 min, 4 °C), the supernatant
was taken out and evaporated using a rotary centrifuge at 35
°C. Metabolites were redissolved in HPLC buﬀer to obtain the
original sample concentration. Freeze-dried liver samples (50
mg) were extracted with 1.5 mL of methanol (80%). Samples
were sonicated for 30 min at room temperature and centrifuged
(20 000g, 20 min, 4 °C), supernatants were evaporated as
previously described, and then metabolites were redissolved in
200 μL of HPLC buﬀer. One μL sample was injected in the
entire LC−MS analysis.
LC−MS Operation
The LC−MS analyses were performed with a MicrOTOF-Q
mass spectrometer (Bruker Daltonics, Bremen, Germany)
coupled to an Agilent 1200 series capillary HPLC (Agilent,
Santa Clara, CA), as previously described.20 In brief, separation
was performed on a ZORBAX SB C18 column (0.5 × 150 mm,
3.5 μm, Agilent Technologies, Waldbronn, Germany) at 25 °C
using a gradient of water and acetonitrile containing 0.1%
formic acid. All analyses were carried out in duplicate, and the
MS was operated in negative mode. For MS/MS analysis, an
ion intensity threshold of 2000 ion counts was set, and the
three most intense peaks were fragmented. Peaks that appeared
in three consecutive spectra were excluded from fragmentation
for 1 min. Fragmentation was obtained with collision energy of
15−50 eV.
LC−MS Data Analysis
The mass spectra were automatically calibrated in Hystar
(Bruker Daltonics, Bremen, Germany) and processed using
MZmine (version 2.2),21 as previously described.20 For urine
mass spectral data, compound features extracted with MZmine
were subjected to multivariate data analysis using SIMCA-P+
(Umetrics AB, Umea,̊ Sweden). Peak areas were normalized to
the total peak area and each variable was mean-centered and
autoscaled. PC analysis revealed a clear separation between the
three groups. Principal component (PC) 1, describing 14.1% of
the variation, discriminated between the low-fat and high-fat
diets, while the whey and casein diets could be discriminated
along PC 3 (9.8% of the variation). To select the metabolites
that contributed most signiﬁcantly to the discrimination
between the whey and casein diet, an orthogonal partial least-
squares discriminant analysis (OPLS-DA) was performed, and
features with variable importance (VIP) signiﬁcantly higher
than 1 were selected (in total 92 features). Tentative
identiﬁcations were obtained by search against Human
Metabolome Database (HMDB) using MZmine. The resulting
molecular formulas were further checked by SmartFormula
software (Bruker Daltonics) on the basis of high mass accuracy
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(<2 mDa) and well-matched isotopic pattern (mSigma score
<20). Structures were determined using tandem mass
spectrometry and comparison with pure standards or data
posted on metabolite databases (HMDB, Metlin).22,18 The
software Metaboanalyst23 was used for the identiﬁcation of
signiﬁcant metabolic pathways and reports the pathway
signiﬁcance (p) values calculated by the software. (See the
Supporting Information.)
Statistical Analyses
All data represent mean ± SE. All data sets were tested for
homogeneity of variances using the Levene’s test. Data with
heterogeneous variances were log-transformed before statistical
analyses. Growth curves were analyzed using repeated measure-
ment ANOVA using a Fisher LSD test for post hoc
comparisons. The rest of the data were analyzed using one-
way ANOVA with Fisher LSD as post hoc test or Student’s t
test (targeted LC−MS metabolomics in liver and plasma). In
the case of heterogeneous variances after log-transformation,
metabolomic data were analyzed by Kruskal−Wallis test, as
indicated in Table 1. A value of P < 0.05 was considered as
statistically signiﬁcant. Statistics were performed with STATIS-
TICA 9.0 (StatSoft, USA).
■ RESULTS
Whey Feeding Reduced Adipose Tissue Mass and Hepatic
Lipid Accumulation
In accordance with previous studies in C57BL/6J mice,10−12 we
found reduced body mass gain in HF-whey-fed compared with
HF-casein-fed mice, and the diﬀerence was signiﬁcant from
week 4 to week 6 (Figure 1A). Moreover, the cumulative
energy intake was equal between the HF-casein-fed and HF-
whey-fed mice (both 2.60 MJ/42days), and also the apparent
fat digestibility (96.5 ± 0.3 and 96.2 ± 0.2%, respectively) and
apparent nitrogen digestibility (94.9 ± 0.2 and 95.3 ± 0.1%,
respectively) were equal. Thus, at equal energy intake, the HF-
whey-fed mice gained less body mass. The reduced body mass
could be ascribed to lower white adipose tissue masses (Figure
1C), whereas no diﬀerence was observed in iBAT (Figure 1C)
or lean tissue masses (Figure 1B) between the high fat fed mice.
However, the HF-casein-fed mice had signiﬁcantly lower tibialis
anterior muscle mass, relative to the LF reference fed mice,
whereas HF-whey-fed mice did not show this reduction in
muscle mass (Figure 1B). Plasma leptin concentration (Figure
1D), which is generally proportional to adipose tissue mass,24,25
was borderline diﬀerent (ANOVA univariate test, P = 0.059).
No diﬀerence was found in plasma concentration of
adiponectin between the two high-fat-diet-fed groups (Figure
1D). In line with the lower white adipose tissue masses, the
mice fed the HF whey diet appeared to have smaller eWAT and
Table 1. Explorative LC−MS Metabolomic Analysis of 48 h Urine Collected from Mice Fed HF Casein, HF Whey, or LF
Reference Dietsa
ion count
metabolite m/z RT HF casein HF whey LF reference change (%)b pathwayc
pyruvic acid 87.007 3.5 62 ± 32B 304 ± 29A 141 ± 16B 385 1−8, 10, 11, 15−24
citric acid 191.020 3.6 9069 ± 3531B 37231 ± 3936A 17000 ± 815B 311 1, 2
cis-aconitic acidd 173.009 5.9 2077 ± 293B 7625 ± 1525A 4893 ± 409A 267 1, 2
isocitric acide 191.020 2.8 2480 ± 373B 4085 ± 364A 3139 ± 61AB 65 1, 2
succinic acidd 117.019 4.1 58 ± 13B 921 ± 182A 123 ± 11B 1488 1, 2, 9, 11, 15, 16
citramalic acide 147.030 3.2 209 ± 23B 1323 ± 309A 339 ± 34B 533
N-acetylglutamined 187.071 3.1 468 ± 32B 1052 ± 113A 967 ± 49A 124 26
N-acetyl-L-glutamic acid 188.057 3.8 387 ± 59B 740 ± 94A 549 ± 26AB 91 26, 27
hippuric acid 178.051 10.8 3806 ± 218B 2130 ± 128C 7055 ± 201A −44 10
4-OH-benzoic acid 137.025 10.4 317 ± 20A 232 ± 12B 316 ± 8A −27 10
p-OH-phenylacetic acid 151.039 11.9 612 ± 35B 439 ± 28C 819 ± 27A −28 10, 11
4-OH-phenyllactic acid 181.051 9.4 10001 ± 918A 5663 ± 947B 7901 ± 429AB −43 11
kynurenic acid 188.036 11.0 900 ± 36C 1475 ± 77A 1216 ± 36B 64 13
xanthurenic acid 204.030 10.3 6685 ± 434B 12368 ± 1520A 6719 ± 212B 85 13
glutaconic acid 129.018 6.4 1452 ± 157C 5101 ± 183A 2858 ± 378B 251 13, 25
orotic acidd 155.008 3.5 163 ± 14C 522 ± 68A 293 ± 18B 220 12
ureidopropionic acid 131.045 3.0 176 ± 23B 359 ± 61A 311 ± 22AB 103 5, 12, 13
3-furoic acid 111.009 6.7 296 ± 46B 1053 ± 157A 689 ± 48A 256
4-sulfobenzyl alcohol 187.007 20.6 94596 ± 7417A 50780 ± 7844B 76237 ± 1683A −46
p-cresol glucuronide 283.083 12.2 14458 ± 1154A 8382 ± 1686B 15082 ± 491A −42
trans-aconitic acid 173.009 5.1 212 ± 44B 504 ± 50A 479 ± 26A 137
aLC−MS data were obtained in negative mode, and mass to charge ratio (m/z) and retention times (RT) for the given metabolites are given. Ion
counts are reported as mean ± SEM (n = 6−8, except for glutaconic acid, n = 3−7). Numbers with diﬀerent capital letters across columns are
signiﬁcantly diﬀerent, p < 0.05. bThe change represents percent change in the HF Whey group relative to the HF casein group, with negative values
for decrease and positive values for increase. cNumbers refer to metabolic pathways that the metabolites participate in 1, TCA cycle; 2, glyoxylate and
dicarboxylate; 3, pyruvate; 4, glycolysis and gluconeogenesis; 5, pantothenate and CoA biosynthesis; 6, Val, Leu, Ile; 7, Cys, Met; 8, Gly, Ser, Thr; 9,
propanoate; 10, Phe; 11, Tyr; 12, pyrimidines; 13, Trp; 14, purines; 15, butanoate; 16, Ala, Asp, and Glu; 17, taurine and hypotaurine; 18, vitamin
B6; 19, ascorbate and aldarate; 20, pentose phosphate pathway; 21, pentose and glucuronate interconversions; 22, nicotinate and nicotinamide; 23,
terpenoid backbone biosynthesis; 24, β-Ala; 25, Lys, OH-Lys; 26, Gln and Glu; 27, urea cycle; 28, Acyl-CoA and Gly. (−) Metabolites without
known pathway annotation. dFisher LSD test performed on log-transformed data. eStatistics by Kruskal−Wallis test. Numbers with diﬀerent capital
letters (A-C) across columns are signiﬁcantly diﬀerent, P < 0.05.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr500039t | J. Proteome Res. 2014, 13, 2560−25702563
iWAT adipocytes compared with mice fed HF casein (Figure
1E).
Previously, we have observed in mice14,26−28 and in rats29,30
that reduced adiposity was associated with increased adipose
tissue expression of genes involved in energy metabolism and
dissipation of energy in the form of heat. Therefore, we
measured mRNA expression of Ucp1 (uncoupling protein 1),
Ppargc1a (peroxisome proliferator-activated receptor gamma
coactivator 1 alpha), Dio2 (deiodinase, iodothyronine, type II),
and Cpt1b (carnitine palmitoyltransferase 1b) in iWAT and
iBAT. We also measured Ucp3 (uncoupling protein 3) and
Cpt1b mRNA expression in fat-oxidizing slow ﬁber-type skeletal
muscle soleus. No diﬀerences in the expression of these genes
were found between mice fed the HF casein and the HF whey
diets (Figure S2A−C, Supporting Information). Thus, our data
did not indicate that the reduced adipose tissue mass in the HF-
whey-fed mice was due to increased dissipation of energy in the
form of heat as compared with the HF-casein-fed mice.
Visceral adipose tissue mass is correlated with intrahepatic
triglyceride content, and hepatic lipid accumulation might be a
Figure 1. Reduced energy deposition as adipose tissue mass and hepatic lipids in mice fed HF whey diets. From weeks 4−6 of the feeding trial, HF
casein had higher body mass than HF whey and LF reference fed mice (A). Both HF-fed groups had lower liver tissue mass, whereas only HF-casein-
fed mice had reduced tibialis anterior (skeletal muscle) mass compared with LF reference fed mice (B). Both HF whey and LF reference fed mice
had reduced white adipose masses, relative to HF-casein-fed mice (C). No diﬀerence was observed in nonfasted plasma concentrations of
adiponectin or leptin (D). Adipocyte size in eWAT and iWAT seemed reduced in HF whey, relative to HF-casein-fed mice. Scale bar represents 50
μm (E). Reduced liver total lipids and TAG concentration in HF whey and LF reference compared with HF-casein-fed mice (F). Both HF groups
have higher nonfasted plasma total cholesterol, and HF-whey-fed mice also had higher free fatty acid (FFA) concentration, relative to LF reference
fed mice (G). Abbreviations: Kid, kidneys; Tib, tibialis anterior; Sol, soleus; eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose
tissue; iBAT, interscapular brown adipose tissue; TAG, triacylglycerol; PL, phospholipids; FFA, free fatty acids, OH-but, hydroxybutyrate. Values are
given as mean ± SEM (n = 12−14: A, Liver, Tib in B, C; n = 5−8: Kid, Heart, Sol in B, D, F, G). Signiﬁcant diﬀerences marked by # (P < 0.02 HFC
vs LF and HFW); * (P < 0.05); ** (P < 0.01); *** (P < 0.001).
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good marker of the metabolic derangements associated with
obesity.31 In the present study, the HF-whey-fed mice had
signiﬁcantly lower liver total lipids and triacylglycerol (TAG)
concentrations than the mice fed the HF casein diet, indicating
less ectopic fat accumulation in these mice (Figure 1F). Despite
the lower hepatic TAG level in HF-whey-fed mice, we observed
diﬀerences in neither hepatic expression of genes involved in de
novo fatty acid synthesis (Figure S3A, Supporting Information)
nor ex vivo hepatic fatty acid oxidation capacity compared with
the HF-casein-fed mice (Figure S3B, Supporting Information).
Gene expression analyses have previously indicated that hepatic
oxidative phosphorylation was up-regulated in obese diabetic
subjects.32 Similarly, proteomic studies in diabetic rats pointed
in the same direction,33 and increased hepatic oxidative
phosphorylation was reported for high-fat-fed mice.34 In the
present study, the HF-casein-fed mice had signiﬁcantly higher
hepatic gene expression of Hmgcs2 (3-hydroxy-3-methylglutar-
yl-coenzyme A synthase 2) relative to the LF-fed mice (Figure
S3C, Supporting Information). Moreover, hepatic expression of
Acadm (medium-chain acyl-CoA dehydrogenase) was border-
line (ANOVA Univariate Test, P = 0.051) diﬀerent (Figure
S3C, Supporting Information). In contrast, the HF-whey-fed
mice did not show signiﬁcant diﬀerent hepatic expression of
genes involved in fatty acid oxidation relative to the LF fed
mice (Figure S3C, Supporting Information).
Figure 2. Explorative 1H NMR analyses of urine from mice fed LF reference, HF casein, or HF whey diets. During week 4 of the study, urine was
collected for 48 h (LF n = 6 and HF n = 8/ diet). Loadings are shown for OPLS-DA models of mice fed HF casein and LF control (A), HF whey and
LF control (B), and HF casein and HF whey diets (C). All OPLS-DA models have one predicted and one orthogonal component. Quality
parameters for OPLS-DA models: HF casein and LF control (A), (R2X = 0.69, R2Y = 0.92, Q2 = 0.59, CV-ANOVA p value = 0.068); HF whey and
LF control (B) (R2X = 0.71, R2Y = 0.90, Q2 = 0.70, CV-ANOVA p value = 0.019), and HF casein and HF whey (C) (R2X = 0.29, R2Y = 0.93, Q2 =
0.63, CV-ANOVA p value = 0.03). The metabolites are colored according to high urinary concentration in mice fed HF casein (red), HF whey
(blue), and LF control (black), as indicated by the loadings of the predictive component.
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Because hepatic steatosis is associated with adverse
alterations in glucose, fatty acid, and lipoprotein metabolism,35
we measured parameters related to plasma lipids and glucose
metabolism. Nonfasted plasma concentration of total choles-
terol was higher in both of the high-fat-fed groups relative to
the LF-fed mice (Figure 1G). No diﬀerence was observed in
nonfasted plasma concentrations of TAG or glycerol or in the
ketone body β-hydroxybutyrate (OH-butyrate) (Figure 1G).
The nonfasted plasma concentration of free fatty acids (FFAs)
was higher in the HF-whey-fed mice compared with the LF fed
mice and tended (P = 0.06) to be higher than in the HF-casein-
fed mice (Figure 1G). No diﬀerence in nonfasted plasma
glucose, lactate, insulin, or glucagon concentrations was found
(Figure S4A,B, Supporting Information). However, hepatic
gene expression of the rate-limiting enzyme in gluconeogenesis
Pck1 (phosphoenolpyruvate carboxykinase 1) was signiﬁcantly
reduced in the HF-whey-fed and LF-fed relative to the HF-
casein-fed mice (Figure S4C, Supporting Information).
Thus, at equal energy intake and uptake and with no
indications of diﬀerent loss of energy through dissipation of
energy in the form of heat, the HF-whey-fed mice had reduced
energy storages, evident as lower white adipose tissue masses
and lower hepatic lipid accumulation compared with HF-
casein-fed mice.
Urinary 1H NMR Analyzes Revealed Diﬀerent Urine
Excretion Pattern in Mice Fed HF Casein and HF Whey Diet
Metabolites present in urine reﬂect whole body metabolism,
and NMR-based metabolomics on urine has previously been
used in nutritional studies to explore both exposure and
endogenous markers related to diet.36−39 To further elucidate
how HF whey feeding could induce a phenotype with less
energy accretion as body fat, we utilized an explorative analysis
of the 48 h urine by 1H NMR spectroscopy using supervised
OPLS-DA between the HF casein and LF reference (Figure
2A) between the HF-whey-fed and the LF-reference-fed
(Figure 2B) and between the HF-whey-fed and HF-casein-fed
(Figure 2C) mice. The urine from LF-reference-fed mice
contained larger amounts of sucrose, glucose, and molecules
within the sugar region relative to the urine from the HF-fed
mice (Figure 2 A,B), probably due to the higher carbohydrate
content in the LF reference diet (Table S1 in the Supporting
Information). The urinary content of trimethylamine appeared
to be associated with the consumption of casein, as it was
higher in urine from both LF reference and HF-casein-fed,
relative to that in urine from HF-whey-fed mice (Figure 2A−
C). Urinary taurine excretion (Figure 2A−C) appeared to
follow the dietary content of its precursor molecule cysteine
(Table S3 in the Supporting Information). When comparing
the two groups of HF-fed mice, the urine of HF-whey-fed mice
contained higher levels of metabolites such as the simple
carboxylate anion formate (singlet, 8.46 ppm), the purine
degradation product allantoin (singlet, 5.40 ppm), the sulfur
amino acid metabolite taurine (triplet, 3.27 ppm; triplet, 3.44
ppm), and the TCA cycle intermediates citrate (doublet, 2.59
ppm; doublet, 2.73 ppm) and succinate (singlet, 2.45 ppm). In
the HF-casein-fed mice, the urinary concentration of the
metabolites sucrose (major peaks: singlet, 3.67 ppm; multiplet,
3.83 ppm), creatinine (singlet, 3.06 ppm; singlet, 4.10 ppm),
the tertiary amine trimethylamine (singlet, 3.90 ppm), and the
glucose metabolite lactate (doublet, 1.33 ppm; the other proton
signal was heavily overlapped by sucrose signal at 4.04 ppm)
were present at higher concentrations (Figure 2C).
Urinary Metabolomes Diﬀer with Regard to TCA Cycle
Intermediates and Amino Acid Metabolites
To further explore the diﬀerences in the urinary metabolome,
we performed an explorative LC−MS metabolomic analysis on
the 48 h urine, which provided a higher sensitivity than the
applied 1H NMR analyses. For identiﬁcation of metabolic
pathways diﬀerently regulated in the HF whey and HF-casein-
fed mice, the obtained LC−MS data were analyzed by the
Metaboanalyst software. This approach unveiled that in
particular TCA cycle metabolism but also metabolic pathways
involved in amino acid, carbohydrate, purine, pyrimidine,
glycolysis, and gluconeogenesis were diﬀerently regulated in the
HF-whey-fed and HF-casein-fed mice (Figure 3 and Table 1).
Conﬁrming our ﬁndings from 1H NMR spectroscopy, our LC−
MS analyses showed that the mice fed HF whey diet had
signiﬁcantly higher urinary intensities of the TCA-cycle
intermediates citric acid and succinic acid, relative to HF-
casein-fed mice (Table 1). In addition, the LC−MS analyses
also identiﬁed higher urinary intensities of the TCA cycle
intermediates cis-aconitic acid and isocitric acid and of the
TCA-precursor pyruvate in the HF whey, relative to in the HF-
casein-fed mice (Table 1). Moreover, the HF-whey-fed mice
had higher urinary ion count of citramalic acid, a methylated
analogue of malic acid, relative to the HF-casein-fed mice
(Table 1). Interestingly, the HF-whey-fed mice had higher
urinary ion counts of N-acetylglutamine and N-acetyl-L-
glutamic acid, metabolites from glutamine and glutamate
metabolism, respectively, relative to the HF-casein-fed mice
(Table 1). The dietary amount of glutamate and glutamine was
lower in the HF whey, relative to the HF casein diet (Table S3
Supporting Information). This ﬁnding might indicate diﬀer-
Figure 3. Urinary pathway overview of the explorative LC−MC
analysis from mice fed HF casein or HF whey diets. Explorative LC−
MS analysis was performed on urine sampled for 48 h from mice fed
HF casein or HF whey diets (n = 8/diet). By use of the software
Metaboanalyst 2.0, the urinary metabolome was matched with
metabolic pathways. The metabolome view above shows matched
pathways according to p values (y axis) from pathway enrichment
analysis and pathway impact values (x axis) from pathway topology
analysis. The TCA cycle pathway identiﬁed in the upper right corner is
of greater importance for the separation of the urine metabolome
between treatments.
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ences in glutamate and glutamine metabolism between the two
high-fat-fed groups.
The LC−MS urinary metabolome analyses also indicated
diﬀerences in metabolites associated with phenylalanine and
tyrosine catabolism, that is, hippuric acid, 4-hydroxybenzoic
acid, p-hydroxyphenylacetic acid, and 4-hydroxyphenyllactic
acid between the HF-whey-fed and the HF-casein-fed mice
(Table 1), which are in accordance with the amino acid
composition in the diets (Table S3 in the Supporting
Information). Likewise, the urinary diﬀerences in metabolites
associated with tryptophan or lysine catabolism, that is,
kynurenic acid, xanthurenic acid, and glutaconic acid (Table
1), reﬂected the dietary content of these amino acids (Table S3
Supporting Information). The HF-whey-fed mice had higher
urinary ion counts of orotic acid and ureidopropionic acid than
the HF-casein-fed mice (Table 1). Interestingly, urinary
excretion of several metabolites related to TCA cycle,
glutamine/glutamate metabolism, and purine/pyrimidine me-
tabolism was intermediate in the LF reference fed, relative to
mice fed HF whey or HF casein diets (Table 1).
Our data from the urine metabolome indicated that in
particular TCA metabolism was altered between mice fed HF
whey or HF casein diets. To explore whether changes in TCA
intermediate concentrations were also evident in the liver and
plasma, we performed targeted LC−MS analyses. In the fed
state plasma but not liver signiﬁcantly elevated ion counts of
citric acid and cis-aconitic acid were found in the HF whey
relative to HF-casein-fed mice (Table 2). Thus, changes in
TCA cycle metabolism were evident both from fed state plasma
and from 48 h urine metabolome analyses, which might be an
underlying mechanism to the reduced body lipid accretion in
HF whey compared with HF-casein-fed mice.
■ DISCUSSION
The present study showed that at equal energy intake and
apparent nitrogen and -fat digestibility, HF-whey-fed mice
stored less energy as lipids, evident both as lower white adipose
tissue mass and as reduced liver lipids compared with HF-
casein-fed mice. Our data are in agreement with other studies
feeding high fat casein or whey diets to mice.10−12 Gene
expression analyses of white and brown adipose tissues as well
as skeletal muscle did not support the fact that the reduced lipid
deposition was associated with increased dissipation of energy
in the form of heat. Moreover, hepatic gene expression analyses
and ex vivo hepatic fatty acid oxidation measurements did not
support the fact that lipids were diﬀerently catabolized in livers
of the HF whey and HF-casein-fed mice. Our data are
supported by the ﬁndings of McAllan et al., who did not
observe diﬀerent heat production between mice on HF casein
and HF whey diets.11
Our 48 h urinary metabolome analyses provided evidence as
to how HF whey feeding might reduce body energy deposition
relative to HF casein feeding in mice, namely, through altered
TCA cycle metabolism, veriﬁed by both 1H NMR-based and
LC−MS metabolomics. Enhanced urinary excretion of TCA
cycle intermediates by HF whey feeding represents a direct loss
of energy through drainage of carbon-containing molecules
from the body. In addition to the direct loss of energy, removal
of substrates from the TCA cycle might also have contributed
to reduced lipid accretion because TCA cycle intermediates and
citrate, in particular, have been shown to stimulate fatty acid de
novo synthesis.40 The stimulation of lipogenesis by citrate is
multifaceted; ﬁrst, citrate is the major carrier in the transfer of
acetyl groups from the mitochondria to the cytosol, where the
fatty acid synthesis occurs.41 Second, citrate is an allosteric
activator of acetyl-CoA carboxylase (ACC), the rate-limiting
enzyme in fatty acid synthesis.42 Third, in the cytosol, citrate
can be metabolized by the action of ATP-citrate lyase to yield
oxaloacetate and acetyl-CoA, the latter being the substrate for
ACC. Finally, cytosolic oxaloacetate is metabolized to malate,
which by the action of malic enzyme can be further metabolized
to pyruvate, a reaction that generates reduced nicotinamide
adenine dinucleotide phosphate (NADPH), the reducing
equivalent needed for fatty acid synthesis. Thus, in the present
study, the higher urinary intensities of the TCA cycle
intermediates in the HF-whey-fed mice relative to the HF-
casein-fed mice suggest that fewer TCA cycle intermediates
were available for lipid synthesis. This is likely to be important
for the reduced body lipid accretion in general and for the
lower hepatic lipid levels in the HF-whey-fed mice observed in
the present study as well as by others.10
Our 1H NMR metabolome analyses of 48 h urine also
revealed that the HF-casein-fed mice had higher signal intensity
of lactate than the HF-whey-fed mice. Elevated urinary lactate
concentration might indicate an enhanced whole body
glycolysis rate. High rates of glucose catabolism and lactate
production, even in the presence of oxygen (aerobic glycolysis),
were ﬁrst described in cancer cells43 and are known as the
Table 2. Targeted LC−MS Analysis in Plasma and Livers Collected from Non-Fasted Mice Fed HF Casein or HF Whey Dietsa
ion count
metabolite m/z RT HF casein HF whey P value change (%)b
Plasma
citric acid 133.014 5.3 150934 ± 15691 211928 ± 16135 0.019 40
cis-aconitic acid 173.009 5.7 13917 ± 1 982 20319 ± 1239 0.018 46
L-malic acid 133.014 5.3 3348 ± 836 4852 ± 1213 0.31 45
succinic acid 117.02 4.3 60003 ± 4265 55579 ± 7374 0.61 −7
fumaric acidc 115.004 5.3 3876 ± 592 3496 ± 322 0.69 −10
Liver
citric acid 133.014 5.3 120730 ± 11342 117688 ± 12096 0.86 −3
cis-aconitic acid 173.009 5.7 103527 ± 15497 95481 ± 13699 0.70 −8
L-malic acid 133.014 5.3 380520 ± 51786 411773 ± 45487 0.65 8
fumaric acid 115.004 5.3 178735 ± 19996 183413 ± 22171 0.87 3
aLC−MS data were obtained in negative mode, and mass to charge ratio (m/z) and retention times (RTs) for the given metabolites are given. Ion
counts are reported as mean ± SEM (n = 6−8). bChange represents percent change in the HF whey group relative to the HF casein group, with
negative values for decrease and positive values for increase. cStudent’s t test performed on log-transformed data.
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“Warburg eﬀect”. Beyond transformed cells, many other cell
types use aerobic glycolysis during proliferation, and it has been
suggested that the major function of aerobic glycolysis is to
provide glycolytic intermediates to support anabolic reactions
in cells.44 In glioblastoma cells exhibiting the Warburg eﬀect,
the exit of TCA intermediates (cataplerosis) was shown to
support fatty acid synthesis, and 60% of the fatty acyl carbons
were estimated to be glucose-derived.45 Moreover, glutaminol-
ysis (i.e., the conversion of glutamine to lactate) was suﬃciently
high to both provide necessary NADPH to support fatty acid
synthesis and to supply anaplerotically oxaloacetate to the TCA
cycle.45 Recently, glutaminolysis was shown to activate
mammalian target of rapamycin complex 1,46 further linking
glutamine metabolism to anabolic processes in cells. In the
present study, despite ∼13% higher dietary content of
glutamine and glutamate in the HF casein diet than in the
HF whey diet, the HF-casein-fed mice had about two-fold
lower urinary signals from the glutamine and glutamate
metabolites N-acetyl glutamine and N-acetyl-L-glutamic acid,
respectively, compared with the HF-whey-fed mice. This
notion, together with the elevated urinary lactate (which may
originate from glutaminolysis) in the HF-casein-fed rats,
indicated that the glutaminolysis was elevated in these animals,
providing a carbon source that facilitated glucose conversion to
lipids in the HF-casein-fed mice relative to in the HF-whey-fed
mice.
It has been shown that rats fed an HF casein diet had
increased hepatic and reduced urinary concentrations of TCA
intermediates (in particular, citrate) relative to rats on a low fat
casein diet.47 Several factors are known to stimulate urinary
citrate excretion (metabolic alkalosis, organic acids, TCA cycle
inhibitors), whereas metabolic acidosis is known to reduce
urinary citrate excretion.48 In the present study, urinary lactate
concentration was higher in urine from the HF-casein-fed mice
compared with the HF-whey-fed mice, and it is possible that
the higher lactate level might have contributed to a slight
metabolic acidosis suppressing TCA cycle intermediate
excretion. Furthermore, plasma from HF-whey-fed mice
contained higher levels of the organic acids citrate and cis-
aconitic acid that might have contributed to enhanced urinary
excretion of TCA cycle intermediates. In addition, urine from
HF-whey-fed mice contained higher levels of citramalic acid,
which possibly can act as a fumarase inhibitor,49 thereby
promoting increased urinary TCA cycle excretion.
Despite higher 48 h urine TCA cycle intermediate excretion
in HF-whey-fed mice that could be an underlying factor to the
reduced fat accretion in these mice, we did not observe
diﬀerences in hepatic expression of genes related to lipogenesis.
It is possible that the lipogenic ﬂux was diﬀerent without
altering gene expression. Alternatively, lipogenesis was
unaltered in the liver but was altered in extrahepatic tissues.
Previously, a strong correlation has been demonstrated between
TCA cycle ﬂux and Pck-1 ﬂux (gluconeogenesis) both in
humans50 and in mice.51 Moreover, endogenous glucose
production has been demonstrated to be elevated in HF
casein, relative to in LF reference fed mice.52 In the present
study, hepatic Pck-1 gene expression was higher in the HF-
casein-fed mice, which could indicate higher hepatic gluconeo-
genesis. Furthermore, as long as the mice remained insulin-
sensitive, it could be speculated that the glucose was eﬀectively
taken up by peripheral tissues, such as skeletal muscle and white
adipose tissue. In adipose tissue, the glucose could be used in
de novo lipogenesis.53 Such a scenario is in keeping with the
observation of increased concentration of TCA cycle
intermediates in plasma but not in liver, potentially reﬂecting
diﬀerences in extrahepatic TCA cycle metabolism. Moreover,
the higher 48 h urine lactate levels observed in the HF-casein-
fed mice could also be caused by higher muscle glucose
oxidation.
The diﬀerent amino acid composition in the HF casein and
HF whey diets is likely to have contributed to the diverging
phenotypes of mice in the present study. Amino acid
metabolism is linked to both carbohydrate and fat metabolism
through the TCA cycle. The HF whey diet contained
particularly high amounts of alanine (+81%), aspartate/
aspargine (+74%), threonine (+82%), and trytophane (+54%)
relative to the HF casein diet, and because these amino acids
are linked to the TCA cycle54 it is likely that the higher urinary
TCA cycle intermediate excretion reﬂected diﬀerences in amino
acid metabolism, which would have direct inﬂuence on anabolic
processes in the mice. Moreover, it has been shown that
supplementing casein-based low-protein diets with threonine +
lysine prevented hepatic lipid accumulation in young rats,55
whereas partial exchange of casein by a mixture of leucine,
isoleucine, valine, threonine, and lysine in high-fat diets
prevented hepatic steatosis, body fat accretion, and insulin
resistance in mice, at least partially by reducing de novo
lipogenesis ﬂuxes.56 Caution should be exerted in translating
the ﬁndings from the previously mentioned studies into ours
due to diﬀerent experimental settings. However, the HF whey
diet in the present study had ∼46% higher threonine + lysine
content and ∼26% higher leucine + isoleucine + valine +
threonine + lysine level compared with the HF casein diet. The
higher level of these speciﬁc amino acids in the HF whey diet
might be related to the reduced lipid deposition observed in the
HF-whey-fed mice.
Even though we are unable to identify the speciﬁc factor(s)
or the speciﬁc tissue(s) responsible for the observed diﬀerence
in urine metabolome in the present study, it is evident that HF
casein and HF whey feeding induced metabolic changes that
altered urinary TCA intermediate excretion, thereby providing
diﬀerent amounts of TCA cycle intermediates for sustained
anabolic processes that could lead to diﬀerences in body lipid
deposition.
■ CONCLUSIONS
This study has demonstrated that at equal energy intake HF-
whey-fed mice have reduced white adipose tissue masses and
lower hepatic lipid concentrations. These phenotypic alter-
ations are unlikely to be due to diﬀerent fat catabolism. Rather,
1H NMR-based and LC−MS metabolomics analyses unveiled a
higher urinary excretion of TCA cycle precursor and
intermediates in the HF whey relative to the HF-casein-fed
mice. We suggest that this loss of TCA cycle compounds
through urine removes available substrate for lipogenesis,
thereby leading to reduced lipid accretion in the HF-whey-fed
compared with the HF-casein-fed mice. Further studies on
using isotope labeling and ﬂux analysis to quantify the eﬀects
on the TCA metabolism would be of great interest.
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